Source disclosure: March 06, 2026, 17:00 JST
Published by Pulse News Wire: March 06, 2026, 17:05 JST
OncoTherapy Science,Inc. [4564.T]
TOKYO, Mar 06 (Pulse News Wire) – Oncotherapy Science,inc. (4564.T) announced today that it had requested the suspension of exercise for all remaining warrants of issue number 38 (with adjustment clause) held by Long Corridor Alpha Opportunities Master Fund, MAP246 Segregated Portfolio, and BEMAP Master Fund Ltd.
The request was made based on the warrant subscription agreement signed with these allottees. As of today, there are 396,000 outstanding unexercised warrants (equivalent to 39,600,000 ordinary shares).
The cessation of exercise period begins on March 27, 2026 and ends on March 31, 2026. For more detailed information regarding this warrant issuance, interested parties should refer to the announcement published on November 21, 2025, concerning the third-party allocation of new shares and warrant issue number 38 (with adjustment clause).
AI-translated content. 🟢 Confidence: High See terms • Original filing